The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours
H Moch, AL Cubilla, PA Humphrey, VE Reuter… - European urology, 2016 - Elsevier
The fourth edition of the World Health Organization (WHO) classification of urogenital
tumours (WHO “blue book”), published in 2016, contains significant revisions. These …
tumours (WHO “blue book”), published in 2016, contains significant revisions. These …
Renal cancer
U Capitanio, F Montorsi - The Lancet, 2016 - thelancet.com
The diagnosis and management of renal cell carcinoma have changed remarkably rapidly.
Although the incidence of renal cell carcinoma has been increasing, survival has improved …
Although the incidence of renal cell carcinoma has been increasing, survival has improved …
[HTML][HTML] Choosing the right cell line for renal cell cancer research
KK Brodaczewska, C Szczylik, M Fiedorowicz, C Porta… - Molecular cancer, 2016 - Springer
Cell lines are still a tool of choice for many fields of biomedical research, including oncology.
Although cancer is a very complex disease, many discoveries have been made using …
Although cancer is a very complex disease, many discoveries have been made using …
[HTML][HTML] Fumarate hydratase–deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell …
Hereditary leiomyomatosis and renal cell carcinoma syndrome–associated renal cell
carcinomas (RCC) are difficult to diagnose prospectively. We used immunohistochemistry …
carcinomas (RCC) are difficult to diagnose prospectively. We used immunohistochemistry …
[HTML][HTML] Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets
YB Chen, J Xu, AJ Skanderup, Y Dong… - Nature …, 2016 - nature.com
Renal cell carcinomas with unclassified histology (uRCC) constitute a significant portion of
aggressive non-clear cell renal cell carcinomas that have no standard therapy. The …
aggressive non-clear cell renal cell carcinomas that have no standard therapy. The …
Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women
A unique renal neoplasm characterized by eosinophilic cytoplasm and solid and cystic
growth was recently reported in patients with tuberous sclerosis complex (TSC). We …
growth was recently reported in patients with tuberous sclerosis complex (TSC). We …
TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity
Renal cell carcinomas (RCCs) with the t (6; 11)(p21; q12) chromosome translocation are low-
grade RCC which often occur in young patients. They typically feature an unusual biphasic …
grade RCC which often occur in young patients. They typically feature an unusual biphasic …
Tubulocystic carcinoma of the kidney with poorly differentiated foci: a frequent morphologic pattern of fumarate hydratase-deficient renal cell carcinoma
An emerging group of high-grade renal cell carcinomas (RCCs), particularly carcinomas
arising in the hereditary leiomyomatosis renal cell carcinoma syndrome (HLRCC), show …
arising in the hereditary leiomyomatosis renal cell carcinoma syndrome (HLRCC), show …
Active surveillance for renal neoplasms with oncocytic features is safe
PO Richard, MAS Jewett, JR Bhatt, AJ Evans… - The Journal of …, 2016 - Elsevier
Purpose Oncocytomas are benign tumors often diagnosed incidentally on imaging. Small
case series have suggested that the growth kinetics of oncocytomas are similar to those of …
case series have suggested that the growth kinetics of oncocytomas are similar to those of …
Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling
Background Collecting duct carcinoma (CDC) is a rare type of renal cell carcinoma (RCC)
originating from the renal medulla. Clinical outcomes are poor, and there are no consensus …
originating from the renal medulla. Clinical outcomes are poor, and there are no consensus …